374
Views
22
CrossRef citations to date
0
Altmetric
Original Articles

A blood spot method for detecting fumonisin-induced changes in putative sphingolipid biomarkers in LM/Bc mice and humans

, , , , , , , , , , , , & show all
Pages 934-949 | Received 22 Dec 2014, Accepted 02 Mar 2015, Published online: 10 Apr 2015

References

  • Bode C, Sensken SC, Peest U, Beutel G, Thol F, Levkau B, Li Z, Bittman R, Huang T, Tölle M, Van der Giet M, Gräler MH. 2010. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem. 109:1232–1243.
  • Bolger M, Coker RD, DiNovi M, Gaylor D, Gelderblom W, Olsen M, Paster N, Riley RT, Shephard G, Speijers GJA. 2001. Fumonisins. In: Joint FAO/WHO Expert Committee on Food Additives (JECFA), editor. Safety evaluation of certain mycotoxins in food. WHO Food Additives Series 47, FAO Food and Nutrition Paper 74. Geneva: WHO; p. 103–279.
  • Bondy GS, Mehta R, Caldwell D, Coady L, Armstrong C, Savard M, Miller JD, Chomyshyn E, Bronson R, Zitomer NC, Riley RT. 2012. Effects of long term exposure to the mycotoxin fumonisin B1 in p53 heterozygous and p53 homozygous transgenic mice. Food Chem Toxicol. 50:3604–3613.
  • Bulder AS, Arcella D, Bolger M, Carrington C, Kpodo K, Resnik S, Riley RT, Wolterink G, Wu F. 2012. Fumonisins. In: FAO/WHO Expert Committee on Food Additives (JECFA), editor. Safety evaluation of certain food additives and contaminants. WHO Food Additives Series 65. Geneva: WHO; p. 325–794.
  • Callihan P, Zitomer N, Kennedy P, Lynch K, Riley RT, Hooks SB. 2012. Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydro-sphingosine 1-phosphate in human neural progenitor cells. Neuropharmacology. 62:988–996.
  • Gelineau-van Waes J, Rainey MA, Maddox JR, Voss KA, Sachs AJ, Gardner NM, Wilberding JD, Riley RT. 2012. Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720. Birth Defects Res A. 94:790–803.
  • Gelineau-van Waes J, Starr L, Maddox J, Aleman F, Voss KA, Wilberding J, Riley RT. 2005. Maternal fumonisin exposure and risk for neural tube defects: mechanisms in an in vivo mouse model. Birth Defects Res A. 73:487–497.
  • Gelineau-van Waes J, Voss KA, Stevens VL, Speer MC, Riley RT. 2009. Maternal fumonisin exposure as a risk factor for neural tube defects. Adv Food Nutr Res. 56:145–181.
  • Hänel P, Andréani P, Gräler MH. 2007. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 21:1202–1209.
  • International Agency for Research on Cancer (IARC). 2002. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 82, some traditional herbal medicines, some mycotoxins, naphthalene and styrene. Lyon: IARC Press; p. 301–366.
  • Ito K, Anada Y, Tani M, Ikeda M, Sano T, Kihara A, Igarashi Y. 2007. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun. 357:212–217.
  • Kimanya ME, De Meulenaer B, Roberfroid D, Lachat C, Kolsteren P. 2010. Fumonisin exposure through maize in complementary foods is inversely associated with linear growth of infants in Tanzania. Mol Nutr Food Res. 54:1659–1667.
  • Liao YJ, Yang JR, Chen SE, Wu SJ, Huang SY, Lin JJ, Chen LR, Tang PC. 2014. Inhibition of fumonisin B1 cytotoxicity by nanosilicate platelets during mouse embryo development. PLoS One. 9:e112290.
  • Månsson M, Klejnstrup MI, Phipps RK, Nielsen KF, Frisvad JC, Gotfredsen CH, Larsen TO. 2010. Isolation and NMR characterization of fumonisin B2 and a new fumonisin B6 from Aspergillus niger. J Agric Food Chem. 58:949–953.
  • Marasas WFO, Riley RT, Hendricks KA, Stevens VL, Sadler TW, Gelineau-van Waes J, Missmer SA, Cabrera Valverde J, Torres OL, Gelderblom W, Allegood J, Martínez De Figueroa AC, et al. 2004. Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. J Nutr. 134:711–716.
  • Merrill AH, Sullards MC, Wang E, Voss KA, Riley RT. 2001. Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. Environ Health Persp. 109:283–289.
  • Rheeder JP, Marasas WFO, Vismer HF. 2002. Production of fumonisin analogs by Fusarium species. App Environ Microb. 68:2101–2105.
  • Riley RT, Enongene E, Voss KA, Norred WP, Meredith FI, Sharma RP, Spitsbergen J, Williams DE, Carlson DB, Merrill Jr. AH. 2001. Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. Environ Health Persp. 109:301–308.
  • Riley RT, Hinton DM, Chamberlain WJ, Bacon CW, Wang E, Merrill Jr. AH, Voss KA. 1994. Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. J Nutr. 124:594–603.
  • Riley RT, Torres O, Showker JL, Zitomer NC, Matute J, Voss KA, Gelineau-van Waes J, Maddox JR, Gregory SG, Ashley-Koch AE. 2012. The kinetics of urinary fumonisin B1 excretion in humans consuming maize-based diets. Mol Nutr Food Res. 56:1445–1455.
  • Riley RT, Voss KA. 2006. Differential sensitivity of rat kidney and liver to fumonisin toxicity: organ-specific differences in toxin accumulation and sphingoid base metabolism. Tox Sci. 92:335–345.
  • Riley RT, Voss KA, Showker JL, Torres O, Matute J, Maddox JR, Rainey MA, Gardner NM, Sachs A, Gregory SG, et al. 2012. Development of biomarkers to assess fumonisin exposure and birth defects. In: Binder EM, editor. World Nutrition Forum 2012. Leicesterhire: Anytime Publishing; p. 249–256.
  • Riley RT, Wang E, Merrill Jr AH. 1994. Liquid chromatography of sphinganine and sphingosine: Use of the sphinganine to sphingosine ratio as a biomarker for consumption of fumonisins. J AOAC Int. 77:533–540.
  • Shirima C, Kimanya M, Routledge M, Srey C, Kinabo J, Humpf H, Wild C, Tu Y-K, Gong Y. 2015. A prospective study of growth and biomarkers of exposure to aflatoxin and fumonisin during early childhood in Tanzania. Environ Health Persp. 123:173–178.
  • Thuy AV, Reimann CM, Hemdan NY, Gräler MH. 2014. Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem. 34:158–171.
  • Torres O, Matute J, Gelineau-van Waes J, Maddox JR, Gregory SG, Ashley-Koch AE, Showker JL, Zitomer NC, Voss KA, Riley RT. 2014. Urinary fumonisin B1 and estimated fumonisin intake in women from high- and low-exposure communities in Guatemala. Mol Nutr Food Res. 58:973–983.
  • Torres O, Matute J, Gelineau-van Waes J, Maddox JR, Gregory SG, Ashley-Koch SE, Showker JL, Voss KA, Riley RT. 2015. Human health implications from co-exposure to aflatoxins and fumonisins in maize-based foods in the Latin America: Guatemala a case study. World Mycotoxin J. 8:143–159.
  • Torres OA, Palencia E, Lopez De Pratdesaba L, Grajeda R, Fuentes M, Speer M, Merrill Jr AH, O’Donnell K, Bacon CW, Glenn AE, Riley RT. 2007. Estimated fumonisin exposure in Guatemala is greatest in consumers of lowland maize. J Nutr. 137:2723–2729.
  • Van der Westhuizen L, Shephard GS, Gelderblom WCA, Torres O, Riley RT. 2013. Fumonisin biomarkers in maize eaters and implications for human disease. World Mycotoxin J. 6:223–232.
  • Voss KA, Riley RT, Jackson LS, Jablonski JE, Bianchini A, Bullerman LB, Hanna MA, Ryu D. 2011. Extrusion cooking with glucose supplementation of fumonisin contaminated corn grits protected against nephrotoxicity and disrupted sphingolipid metabolism in rats. Mol Nutr Food Res. 55:S312–S320.
  • Voss KA, Riley RT, Snook M, Gelineau-van Waes J. 2009. Comparing the reproductive and sphingolipid metabolic effects of fumonisin B1 and its alkaline hydrolysis product in LM/Bc mice: hydrolyzed fumonisin B1 did not cause neural tube defects. Tox Sci. 112:459–467.
  • Yang L, Yatomi Y, Miura Y, Satoh K, Ozaki Y. 1999. Metabolism and functional effects of sphingolipids in blood cells. Br J Haematol. 107:282–293.
  • Zitomer NC, Glenn AE, Bacon CW, Riley RT. 2008. A single extraction method for the analysis by liquid chromatography/tandem mass spectrometry of fumonisins and biomarkers of disrupted sphingolipid metabolism in tissues of maize seedlings. Anal Bioanal Chem. 391:2257–2263.
  • Zitomer NC, Mitchell T, Voss KA, Bondy GS, Pruett ST, Garnier-Amblard EC, Liebeskind LS, Park H, Wang E, Sullards MC, Merrill Jr AH, Riley RT. 2009. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxy-sphinganine: A novel category of bioactive 1-deoxy-sphingoid bases and 1-deoxy-dihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem. 284:4786–4795.
  • Zitomer NC, Riley RT. 2011. Extraction and analyses of fumonisins and compounds indicative of fumonisin exposure in plant and mammalian tissues and cultured cells. Methods Mol Biol. 739:171–185.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.